bwge2017 has ended

Create Your Own Event

bwge2017

08:30 CET

HMGB1-driven Feedforward Hepatocyte Necroptosis Circuit in Lethal Acetaminophen-induced liver injury. Room LIJN 3rd floorCharlotte Minsart

08:40 CET

Characterization of a tertiary center PBC cohort and validation of prognostic risk scores Room LIJN 3rd floorTim Claes

08:50 CET

Lipid, fetuin-A and macrophage zonation in high fat diet foz-foz mice with non-alcoholic steatohepatitis Room LIJN 3rd floorNicolas LANTHIER

09:00 CET

Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in obese patients with non-alcoholic fatty liver disease Room LIJN 3rd floorSander Lefere

09:10 CET

Ubiquitin Carboxy-terminal Hydrolase L1 expression is increased in hepatocellular carcinoma cells and renders those cells more sensitive to ER stress-induced cell death following inhibition. Room LIJN 3rd floorAstrid Vandierendonck

09:20 CET

Do or don’t: HCV screening in the Belgian Baby Boom Cohort. Room LIJN 3rd floorRuth Botterman

09:30 CET

ECV-associated miRNA levels as non-invasive biomarkers for early-stage HBV/HCV-induced liver fibrosis Room LIJN 3rd floorJoeri Lambrecht

09:40 CET

Pretransplant glycomic analysis of perfusate is predictive of primary non function after liver transplantation Room LIJN 3rd floorXavier VERHELST

09:50 CET

A glycomic serum marker analysed at one week after liver transplantation is an independent predictor of graft loss during the first year after liver transplantation Room LIJN 3rd floorXavier VERHELST

10:30 CET

Relapse rates and clinical outcomes after Nucleos(t)ide Analogue therapy stop in a Belgian, predominantly Caucasian cohort of Chronic Hepatitis B patients Room LIJN 3rd floorStijn Van Hees

10:42 CET

LIVER FIBROSIS PROMOTES HEPATOCARCINOMA GROWTH THROUGH INFILTRATION BY TUMOR-ASSOCIATED INFLAMMATORY CELLS Room LIJN 3rd floorBénédicte Delire

10:54 CET

Paired biopsy analysis of human liver transcriptome before and 1 year after bariatric surgery identifies a restricted set of inflammation- and extracellular matrix-related genes as pivotal in NASH and fibrosis... Room LIJN 3rd floorSven FRANCQUE (UZA)

11:06 CET

Liver progenitor cells significantly contribute to hepatocyte pool in chronic liver injury and cirrhosis: a kinetic study in mice. Room LIJN 3rd floorRita Manco

11:18 CET

Early TIPS placement as a feasible and safe strategy for variceal bleeding in high risk liver patients: a 5-year monocentre experience. Room LIJN 3rd floorEwout Verly

11:30 CET

BLIC Lecture: Liver Transplantation in acute on chronic liver failure Room LIJN 3rd floorThierry Gustot (Erasme ULB)

12:00 CET

Satellite Symposium MSD Room LIJN 3rd floor MSD Satellite symposium Room LIJN 3rd floor

13:15 CET

Satellite Symposium BMS Room LIJN 3rd floor BMS Satellite Symposium Room LIJN 3rd floor

14:00 CET

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): establishment of a unique, innovating animal model with insufficient liver remnant. Room LIJN 3rd floorALEXANDRA DILI

14:12 CET

The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without Pegylated Interferon: A Belgian experience. Room LIJN 3rd floorRob Bielen

14:24 CET

Pegylated interferon alpha treatment rapidly clears Hepatitis E Virus infections in humanized mice. Room LIJN 3rd floorThomas VANWOLLEGHEM

14:36 CET

Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogues is highly effective and reduces cost for hepatitis B prophylaxis after liver transplantation Room LIJN 3rd floorRob Bielen

14:48 CET

PPARα-regulated dermatopontin is an important contributor to the liver fibrotic response in mouse models and has relevance to fibrosis progression in NAFLD patients. Room LIJN 3rd floorPHILIPPE LEFEBVRE

15:00 CET

MARC HAUTEKEETE LECTURE : Do direct antiviral agents for HCV increase risk of hepatocellular carcinoma : fact, fiction or undecided? Room LIJN 3rd floorMarc Hautekeete

16:00 CET

Kupffer cell pool is maintained by local proliferation and the differentiation of bone marrow monocytes into short-lived monocyte-derived Kupffer cells during non-alcoholic steatohepatitis and recovery Room LIJN 3rd floorLindsey DEVISSCHER

16:10 CET

Cessation of Nucleos(t)ide Analogue therapy after HBeAg seroconversion is associated with a decreased chance of HBsAg loss in a Belgian, predominantly Caucasian cohort of chronic hepatitis B patients Room LIJN 3rd floorStijn Van Hees

16:20 CET

A new classification of chronic portal vein occlusion for assessing the feasibility of recanalization in non-cirrhotic patients Room LIJN 3rd floorAstrid Marot

16:30 CET

The prevalence of cardiac induced liver disease in patients with a chronic right heart disorder. Room LIJN 3rd floorFrederik NEVENS

16:40 CET

Invited Lecture : introducing the mandatory registration of follow-up data for patients treated with antiviral hepatitis C medication Room LIJN 3rd floorJohan Van Bussel • Marc Van de Casteele

17:00 CET

BASL Awards for best Basic and Clinical work presented and Update on e-health requirement and BASL General Assembly Room LIJN 3rd floor

07:45 CET

ALLERGAN Satellite Symposium Room LIJN 3rd floor

08:30 CET

INVITED LECTURE: Management of fibrostenosing Crohn’s disease. Room LIJN 3rd floorFlorian Rieder (Cleveland Ohio USA)

09:00 CET

Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with ulcerative colitis undergoing (procto)colectomy with ileal pouch-anal anastomosis Room LIJN 3rd floorMarc FERRANTE

09:10 CET

Adalimumab dose escalation and de-escalation in UC: incidence and predictors of success: a real life Belgian cohort study. Room LIJN 3rd floorSaartje Van De Vondel

09:20 CET

Correlation of durability of response, serum trough concentrations and outcome parameters: long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial. Room LIJN 3rd floorLieven POUILLON

09:30 CET

Recent Anti-TNF Exposure Predicts Lower Vedolizumab Trough Concentrations in Patients with Crohn Disease Room LIJN 3rd floorErwin Dreesen

09:40 CET

Natural history of dysplasia and colorectal cancer in inflammatory bowel disease in Belgium tertiary care centers Room LIJN 3rd floorAnneline Cremer

10:20 CET

INVITED LECTURE : Evolving therapeutic algorithms in UC. Room LIJN 3rd floorBrian Feagan (London Ontario Canada)

10:50 CET

Anti-Infliximab Antibody Concentrations Guide Therapeutic Decision-Making in Patients with Crohn’s Disease Losing Clinical Response Room LIJN 3rd floorErwin Dreesen

11:00 CET

Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn’s disease: results from the Phase 2 FITZROY study Room LIJN 3rd floorVeerle Vyncke

11:10 CET

IBD nurses as integral part of a multidisciplinary IBD team: prospective study on view on patient outcomes Room LIJN 3rd floorSofie COENEN

11:20 CET

INVITED LECTURE: Evolving therapeutic algorithms in CD. Room LIJN 3rd floorLaurent Peyrin-Biroulet (Nancy France)

12:00 CET

TAKEDA Satellite Symposium Room LIJN 3rd floor

13:15 CET

SANOFI Satellite Symposium Room LIJN 3rd floor

14:00 CET

Primary tumor sidedness has an impact on prognosis and treatment outcome: results from three randomized studies of panitumumab plus chemotherapy versus chemotherapy (plus bevacizumab) in 1st and 2nd line RAS/BRAF... Room LIJN 3rd floorNele Boeckx

14:13 CET

Interleukin 15-stimulated natural killer cells can kill both pancreatic cancer and stellate cells Room LIJN 3rd floorEvelien Smits

14:26 CET

Characterization of the immune microenvironment and relation to preoperative treatment of synchronous resection of primary tumor and liver colorectal cancer metastases. Room LIJN 3rd floorMarc VANDENEYNDE

14:39 CET

Prognostic relevance of pancreatic neuroendocrine tumors grading on EUS-FNA Room LIJN 3rd floorIvan BORBATH

14:52 CET

Retrospective study on the incidence of chemotherapy side effects and evaluation of the Hurria score and G8 CGA as predictive tools for toxicity in older patients with gastrointestinal cancer. Room LIJN 3rd floorMarc De Man

15:05 CET

Pressurized intraperitoneal aerosol chemotherapy (PIPAC), a new surgical technique for the treatment of unresectable peritoneal carcinomatosis Room LIJN 3rd floorWouter Willaert

15:45 CET

State-of-the-art lecture: Treatment of borderline resectable pancreatic Cancer: what is the optimal induction treatment? Room LIJN 3rd floorThierry Conroy (Institut de Cancérologie Lorraine Nancy France)

16:15 CET

Upper GI cancers Room LIJN 3rd floorKaren Geboes (UZ Gent)

16:40 CET

Hepato-Bilio-Pancreatic cancers Room LIJN 3rd floorFrancesco Puleo (ULB Erasme)

17:05 CET

Colo-Rectal cancers Room LIJN 3rd floorMarc Peeters (UZ Antwerpen)

17:30 CET

CELGENE Satellite Symposium Room LIJN 3rd floor